Literature DB >> 9296068

Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension.

P Corvol1, F Soubrier, X Jeunemaitre.   

Abstract

Blood pressure is a quantitative trait that varies along a continuum in the general population and is regulated via multiple mechanisms involving many genetic loci and environmental factors. Family studies and twin studies suggest that about 30% of blood pressure variance is attributable to genetic factors and 50% to environmental factors. Two forms of hypertension transmitted on an autosomal recessive basis have been identified: one is glucocorticoid-suppressible hyperaldosteronism (GSH) and the other is Liddle's syndrome (amiloride-suppressible hyperactivity of the epithelial sodium channel). The molecular basis for these two forms of severe hypertension has recently been elucidated. GSH is due to expression of a chimeric gene produced by fusion of the 11 beta-hydroxylase promoter with the region encoding the enzyme aldosterone-synthase. Expression of this chimeric gene occurs in the zona fasciculata of the adrenal cortex, under the control of ACTH, and can be suppressed by administration of glucocorticoids. Liddle's syndrome is due to mutations in the beta or gamma chain of the epithelial sodium channel in distal renal tubule cells. The hyperactivity of this channel caused by the mutations results in increased sodium reabsorption, which can be suppressed by administration of amiloride or triamterene. Apart from these rare genetic defects, a number of susceptibility genes can increase the risk of hypertension in a given environment. Their presence is neither necessary nor sufficient to cause hypertension. The best documented example is the angiotensinogen gene. Angiotensiongen is the substrate of renin, and the renin-angiotensinogen reaction is the first and limiting step in the pathway that leads to production of angiotensin II, a peptide with important effects on blood pressure control and the metabolism of water and sodium. Several studies have demonstrated a link between the angiotensinogen gene and familial hypertension or hypertension of pregnancy. The M235T variant of angiotensinogen is more prevalent among hypertensive than among normotensive subjects in several Caucasian and Japanese populations. The M235T variant is also associated with plasma angiotensinogen elevation, which is potentially responsible for increased production of angiotensin II. In other terms, relationships exist between the angiotensinogen genotype, the intermediate phenotype (i.e., plasma angiotensinogen elevation), and the distal phenomenon (i.e., blood pressure elevation). DNA libraries for the study of hypertension have been set up, and many informative genetic markers distributed along the genome have been identified. Using position cloning techniques, these markers could be used in the search for genetic links between arterial hypertension and a chromosomal locus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9296068

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  17 in total

1.  Transgenic mice with -6A haplotype of the human angiotensinogen gene have increased blood pressure compared with -6G haplotype.

Authors:  Sudhir Jain; Andrej Tillinger; Brahmaraju Mopidevi; Varunkumar G Pandey; Chetankumar K Chauhan; Steven N Fiering; Soren Warming; Ashok Kumar
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

2.  The AGT Gene M235T Polymorphism and Response of Power-Related Variables to Aerobic Training.

Authors:  Zarębska Aleksandra; Jastrzębski Zbigniew; Moska Waldemar; Leońska-Duniec Agata; Kaczmarczyk Mariusz; Sawczuk Marek; Maciejewska-Skrendo Agnieszka; Żmijewski Piotr; Ficek Krzysztof; Trybek Grzegorz; Lulińska-Kuklik Ewelina; Ekaterina A Semenova; Ildus I Ahmetov; Cięszczyk Paweł
Journal:  J Sports Sci Med       Date:  2016-12-01       Impact factor: 2.988

3.  A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice.

Authors:  Brahmaraju Mopidevi; Meenakshi K Kaw; Indu Sivankutty; Sudhir Jain; Sravan Kumar Perla; Ashok Kumar
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

4.  Human aldosterone synthase gene polymorphism promotes miRNA binding and regulates gene expression.

Authors:  Shreekrishna Maharjan; Brahmaraju Mopidevi; Meenakshi Kaul Kaw; Nitin Puri; Ashok Kumar
Journal:  Physiol Genomics       Date:  2014-10-28       Impact factor: 3.107

5.  Association of high-altitude systemic hypertension with the deletion allele-of the angiotensin-converting enzyme (ACE) gene.

Authors:  Ratan Kumar; M A Qadar Pasha; Amjad P Khan; V Gupta; S K Grover; T Norboo; K K Srivastava; W Selvamurthy; S K Brahamchari
Journal:  Int J Biometeorol       Date:  2003-05-13       Impact factor: 3.787

Review 6.  Hypertension in the teenager.

Authors:  Elizabeth I Anyaegbu; Vikas R Dharnidharka
Journal:  Pediatr Clin North Am       Date:  2013-10-30       Impact factor: 3.278

7.  Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding.

Authors:  Brahmaraju Mopidevi; Madhusudhan Ponnala; Ashok Kumar
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

8.  Common genetic risk factors for psychiatric and simatic disorders.

Authors:  Brigitta Bondy
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

Review 9.  Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the Renin-Angiotensin system.

Authors:  Tadashi Konoshita
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

10.  Analysis of renin-angiotensin aldosterone system gene polymorphisms in Malaysian essential hypertensive and type 2 diabetic subjects.

Authors:  Vasudevan Ramachandran; Patimah Ismail; Johnson Stanslas; Norashikin Shamsudin
Journal:  Cardiovasc Diabetol       Date:  2009-02-25       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.